ManagementOpto Circuits gets CE nod for drug sale
Life Sciences technology firm, Opto Circuits, a wholly-owned subsidiary Eurocor has received Communite European (CE) approval to market and sale its Drug Eluting Stent- Taxcor Plus in the world markets.
- Opto to invest Rs 200 cr for units in Vizag, Malaysia - Opto Circuits net up 18% in Q2 - Opto Circuits" US arm signs multi-year supply contract with US firm - Criticare Systems enters into agreement with European firm - Opto Circuits" US arm in supply pact with European firm - Opto Circuits raises Rs 400 cr from QIP issue
"Taxcor Plus is backed by years of research and has shown excellent clinical results," Opto Circuits Chairman & Managing Director Vinod Ramnani said.
The product provides unique therapeutic benefits to patients requiring Drug Eluting Stents for Coronary Angioplasty.
However, the company cannot sell this drug in the US and Japan markets under the terms of the agreement, it said.